The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious ...
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. July 22, ...
Barr Laboratories, a subsidiary of Barr Pharmaceuticals (NYSE: BRL) in Woodcliff Lake, received approval from the Food and Drug Administration to market a generic version of Bristol-Myers Squibb’s ...
Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for didanosine delayed-release capsules, the generic version of Videx EC (from Bristol Myers Squibb). Mylan’s ...
The U.S. Food and Drug Administration announced on January 29 that non-cirrhotic portal hypertension, a rare, but serious, liver disorder, has been reported in some HIV patients taking Videx/Videx EC ...
ROCKVILLE, Md. A rare but serious liver disorder has been reported in some patients taking a drug used to treat HIV, the Food and Drug Administration said Monday. The agency said some patients taking ...
PITTSBURGH A subsidiary of Mylan has won approval from the Food and Drug Administration to market a generic HIV drug under the President’s Emergency Plan for AIDS Relief, Mylan said Monday. The ...
An action to revoke its patent on the drug Videx EC threatens to limit further Bristol-Myers Squibb's (BMS) rights to sell Aids medicines in Thailand. Three Aids patients and the Foundation for ...
WASHINGTON, Feb. 1 (UPI) -- The U.S. Food and Drug Administration says a rare but serious liver disorder has been reported in some HIV patients taking Videx/Videx EC. The FDA said Videx (didanosine) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results